Objective: The mechanisms regulating spiral modiolar artery (SMA) tone are not known, yet their characterization is pivotal for understanding inner ear blood flow regulation. Sphingosine-1-phosphate (S1P), known to stimulate vasoconstriction in several vascular beds, is a candidate regulator of SMA tone with potential pathophysiological relevance. Methods: Gerbil SMAs were isolated, cannulated and pressurized (30 mm Hg transmural) for experimentation under near-in vivo conditions. For functional experiments, vascular diameter and intracellular Ca 2+ were simultaneously measured. Standard RT-PCR and immunohistochemical techniques were also employed. Results: mRNA transcripts encoding sphingosine kinase, S1P phosphohydrolase and three S1P receptors (S1P 1 -3 ) were detected in the SMA. S1P induced dose-dependent vasoconstriction of the SMA (EC 50 = 115 nmol/L), and enhanced the apparent Ca 2+ -sensitivity of the contractile apparatus. Noradrenaline did not elicit vasoconstriction. The Rho kinase inhibitor Y27632 (1 Amol/L) reversed S1P-induced vasoconstriction and the S1P-mediated enhancement of Ca 2+ -sensitivity. RhoA was observed to translocate to the plasma membrane in response to stimulation with 30 Amol/L S1P. Conclusion: We conclude that all key signalling pathway constituents are present at the mRNA level for S1P to act as an endogenous regulator of SMA tone. S1P stimulates potent, RhoA/Rho kinase-dependent SMA vasoconstriction and Ca 2+ sensitization. The high sensitivity to S1P suggests that SMA vasoconstriction is likely to occur under pathological conditions that increase intramural S1P concentrations (i.e., inflammation). From a clinical perspective, the present study identifies new potential therapeutic targets for the treatment of vascular-based, ''stroke-like'' inner ear pathologies: the enzymes responsible for S1P bioavailability and the S1P receptors.
Introduction
The inner ear's blood supply depends solely on the labyrinthine artery and its two branches, the vestibulocochlear and spiral modiolar artery (SMA). These arteries are functional end arteries, without collateral blood supply. Since auditory transduction demands heavy energy consumption [1] , any reduction in SMA blood flow can profoundly impact the auditory apparatus.
Several systemic pathologies (e.g., infection), which often are accompanied by microcirculatory dysfunction, can also affect inner ear function [2] . The resulting auditory and vestibular symptoms possess several key characteristics in common with those of cerebral stroke, including sudden onset, unilateral occurrence and the possibility of resolution within hours to days. Inner ear pathologies share various risk factors in common with cardiovascular diseases [3] and often present clinically as ''stroke-like'', fuelling the hypothesis that they are primarily vascular in origin.
Therapeutic strategies aiming to change the rheological blood properties often fail to improve the clinical condition. A subgroup of sudden sensorineural hearing loss (SSHL) patients was recently reported to have benefited from the removal of plasma low density lipoproteins (LDL) [4] . This interesting clinical observation could potentially advance a pathophysiological concept, where microvascular dysfunction ultimately leads to stroke-like inner ear pathologies. An important cardiovascular risk factor, LDLs, are rapidly oxidized into oxLDL once they enter the vascular wall, and gain pathophysiologically relevant signalling capabilities. In this context, one important effect of oxLDLs is, via activation of sphingosine kinase (Sk1) [5] , that they stimulate the synthesis of the sphingosine-1-phosphate (S1P), which has been shown to induce potent vasoconstriction in mesenteric, cerebral and skeletal muscle microcirculatory beds [6, 7] . Therefore, we speculated that S1P contributes to both the physiological and pathophysiological regulation of SMA tone.
The physiological tone-regulating mechanisms of the SMA are not well understood. Their characterization, however, is pivotal for understanding how vascular resistance and blood flow are controlled in the SMA. In principle, vascular tone can be regulated by Ca 2+ -dependent (via myosin light chain kinase) and/or Ca 2+ -independent (via myosin light chain phosphatase) mechanisms [8] . Based on our previous observation that ET-1 stimulates Ca 2+ -independent SMA vasoconstriction [9] , we speculated that Ca 2+ -independent mechanisms dominate the control of SMA tone. However, since plasma ET-1 levels are much lower than the measured EC 50 , ET-1 is unlikely to be a systemic, bloodborne regulator of SMA tone.
As minimal prerequisites, a physiologically relevant modulator of SMA tone must (i) target prevalent signalling pathways in SMA smooth muscle cells, and (ii) reach an effective concentration in the vascular wall to induce vasoconstriction. In this regard, S1P targets pro-constrictive Rho kinase signalling pathways [6] , has high circulating plasma concentrations [10] and its synthesis within the vascular wall can be induced by several stimuli, for example, increased transmural pressure [11] .
Our group has modified a previously described experimental model in order to investigate the mechanisms regulating SMA tone in pressurized arteries. Using this improved setup, we aimed to: (i) determine the mRNA expression of S1P-signalling elements (i.e., Sk1, S1P phosphohydrolase (SPP1) and S1P receptors 1 -3); (ii) determine the vasomotor response to exogenous S1P; and (iii) measure Ca 2+ -sensitization and RhoA/Rho kinase activation in response to S1P.
Materials and methods

Materials
The Rho kinase inhibitor Y27632 [(+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)] and Sphingosine-1-phosphate (S1P) were purchased from Biomol (Hamburg, Germany 3 .0, and glucose 5.0. Fura-2-AM and Fura Red-AM (Molecular Probes; Leiden, Netherlands) were dissolved in water-free DMSO (Sigma Chemicals; Deisenhofen, Germany) and stored as 1 mmol/L stock solutions at À 80 -C. ''Qiashredder'' mini-spin columns (sample homogenization) and the ''RNeasy Protect Mini Kit'' (mRNA isolation) were purchased from Qiagen (Hilden, Germany); the ''Titan One Tube System'' (RT-PCR) was purchased from Roche (Penzberg, Germany). All other chemicals employed in this study were purchased from Sigma.
Preparation of the spiral modiolar artery
Animal care and experimental protocols were conducted in accordance with German federal animal protection laws and approved by the Institutional Animal Care and Use Committee at the Ludwig-Maximilians University, Munich. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85 -23, revised 1996).
The isolation of the spiral modiolar artery (SMA) has been previously described in detail [12] . Briefly, the gerbil cochlea was isolated, opened and the bone surrounding the modiolus was removed. The SMA was then cautiously dissected away from the eighth cranial nerve, taking care not to stretch the artery. We modified the existing model by cannulating the SMA segments (¨1.5 mm in length) and pressurizing them hydrostatically (30 mm Hg) in order to better simulate in vivo conditions.
All functional experiments were performed at 37 -C in MOPS buffer. As previously described [13] , SMA smooth muscle cells (SMCs) were loaded with Fura-2-AM (2 Amol/ L, 75 min abluminal application) prior to experimentation in order to simultaneously measure changes in smooth muscle Ca 2+ (Photomed; Seefeld, Germany) and outer diameter (custom-made software). For the purpose of obtaining high-quality digital images of SMC Fura loading, Fura Red was employed (2 Amol/L, 20 min abluminal application); vessels were digitally photographed using a Zeiss LSM410 confocal microscope equipped with a Kr/Ar laser and a 63Â/1.2 W water immersion objective. SMA viability was confirmed by testing its vasoconstrictor response to 3 mmol/L Ca 2+ under depolarizing conditions (125 mmol/L KCl).
Since DMSO was used as a solvent for Fura and Y27632, experimental controls for unspecific effects were performed. No effects of DMSO, in its final concentration, were observed with respect to vessel function.
Isolation of mRNA and RT-PCR
Samples of gerbil SMA, aorta, lung and heart tissue were frozen with liquid nitrogen and pulverized with a pestle. The pulverized samples were then suspended in 500 Al ''RTL buffer'' (RNeasy Protect Kit) containing 5 Al h-mercaptomethanol and homogenized with a ''Qiashredder'' mini-spin column. The mRNA was isolated from the resulting homogenate using the RNeasy Protect Kit, according to the manufacturer's instructions. The resulting 50 Al sample was then split into 5 -6 aliquots for subsequent RT-PCR.
One-step RT-PCR of the isolated mRNA samples was completed using the ''Titan One Tube System'', according to the manufacturer's instructions. Primers against rat GADPH, human sphingosine kinase 1 (Sk1), human sphingosine-1-phosphate phosphohydrolase 1 (SPP1) and three rat S1P receptors (S1P 1 -3 ) were employed for Table 1 RT-PCR primers Gene (species)
Primer sequence Amplicon length Sk1 (human) P1: 5V-CCTTCACGCTGATGCTCACTGAGC-3V 693 bp P2: 5V-GGCCCATGGGTGCAGCAAACATCT-3V SPP1 (human) P1: 5V-CTACTGCCTGTTCTGCTTCG-3V 574 bp P2: 5V-TGTGTCTCCTCGGGATGTG-3V S1P 1 (rat) P1: 5V-CTTCAGCCTTGCTATCG-3V 409 bp P2: 5V-GCAGGCAATGAAGACACTCA-3V S1P 2 (rat) P1: 5V-TTCTGGTGCTAATCGCAGTG-3V 695 bp P2: 5V-GAGCAGAGAGTTGAGGGTGG-3V S1P 3 (rat) P1: 5V-TCAGGGAGGGCAGTATGTTC-3V 503 bp P2: 5V-CTGACTCTTGAAGAGGATGG-3V GAPDH (rat) P1: 5V-TATGTCGTGGAGTCTACTGGCGTC-3V 596 bp P2: 5V-GAATGGGAGTTGCTGTTGAAGTCA-3V amplification of cDNA ( Table 1 ). The PCR was carried out as follows: initially, 10 cycles, each containing 10 s denaturation at 94 -C, 30 s annealing at 65 -C and 45 s primer extension at 68 -C; a further 25 cycles were then performed, with the primer extension time increasing 5 s per cycle. The PCR products were separated on a 1.5% Fig. 2 . mRNA expression of S1P signalling constituents. mRNA transcripts encoding sphingosine kinase 1 (Sk1), S1P phosphohydrolase 1 (SPP1) and three S1P receptors (S1P 1 -3 ) were detected in homogenates derived from gerbil SMAs. GAPDH was employed as a positive control for successful RT-PCR. ''M'' denotes the lanes used for the molecular weight marker. Each caption is representative of 5 separate experiments employing pooled homogenates of at least 10 SMAs each. agarose gel, stained with ethidium bromide, and visualized/ photographed with a BioRad Gel Doc 1000 imaging system. GAPDH acted as the positive control for successful RT-PCR.
Immunohistochemistry
Arteries were stimulated with S1P (30 Amol/L) for 30 s and then fixed with 3.7% formaldehyde; control arteries received no stimulation. The fixed vessels were permeabilized with 0.3% Triton X-100, blocked with 1% BSA and incubated with a mouse monoclonal anti-human RhoA antibody overnight at 4 -C (clone 26C4; 1 : 200 dilution; Santa-Cruz Biotechnology, USA). Subsequently, an Alexa 488-labelled rabbit anti-mouse IgG secondary antibody was used (1 : 200 dilution; 90 min at room temperature; Mobitec, Gö ttingen, Germany,). Digital images were obtained by confocal microscopy.
Statistical analysis
All results are expressed as means T SEM of n experiments. Experimental groups, which represented paired observations, were analyzed with a one-way analysis of variance (ANOVA) followed by paired t-tests with Bonferroni correction. Differences were considered to be significant at error probabilities less than 0.05 ( P < 0.05).
Results
Architecture of the SMA vessel wall
The arteries employed in the study possessed an average diameter of 80 T 2 Am (n = 37). In terms of vessel architecture, the SMA is tortuous (Fig. 1a,b) , with several ''straight'' regions (with corresponding regular VSMC alignment) ex . S1P induced a significant enhancement of the apparent Ca 2+ -sensitivity, while a significant reduction in the apparent Ca 2+ -sensitivity was observed in SMAs treated with Y27632 alone or S1P + Y27632. * Denotes significant increase compared to control;
' denotes significant decrease compared to control; and # denotes significant difference between S1P-and S1P + Y27632-treated vessels.
interspersed between rather ''twisted or spiral'' regions (with corresponding irregular/overlapping VSMC alignment). Because our experimental design required us to delicately straighten the vessel (although no longitudinal stretch was applied), we minimized the effect of VSMC geometry by always measuring diameter at one of the ''straight'' regions of the vessel, located at the distal end of its convoluted base. Using confocal imaging and Fura Red-AM, we confirmed that the Fura loading of these arteries was restricted to the smooth muscle cells when it was loaded from the adventitial side (Fig. 1d) ; this has been previously observed in other vessel preparations [13] . Fig. 1d also clearly shows that the SMA possesses only one layer of smooth muscle cells.
3.2. mRNA expression of Sk1, SPP1 and S1P 1 -3 RT-PCR was used to amplify mRNA transcripts encoding proteins that control S1P bioavailability and signalling. These experiments detected the presence of the Sk1 and SPP1 transcripts in the gerbil SMA (Fig. 2) , as well as other gerbil tissues (e.g., the aorta, lung and heart; data not shown). Further, we show that three sphingosine-1-phosphate (S1P) receptors (S1P 1 -3 ; formerly known as Edg1, Edg5 and Edg3), are expressed at the mRNA level in the SMA (Fig. 2) . Because the SMA homogenates were derived from both endothelial and smooth muscle cells, it is not possible to specifically allocate the expression of the respective genes to one or both of the cell types.
Mechanisms underlying S1P-induced vasoconstriction
Representative tracings of SMA diameter and Ca 2+ i measurements following S1P application are displayed in Fig. 3a . S1P induced dose-dependent vasoconstriction, with an EC 50 of 115 nmol/L (pEC 50 = 6.94 T 0.21, n = 11; Fig. 3b) ; after each application of S1P, a concomitant increase in intracellular Ca 2+ was observed, however, these initial responses were transient in nature (Fig. 3a) . The Rho kinase inhibitor Y27632 (1 Amol/L) completely reversed the vasoconstriction induced by the highest dose of S1P (30 Amol/L), indicating the mandatory involvement of the RhoA/Rho kinase signalling pathway (n = 11; Fig. 3a and c) . Noradrenaline (0.1 -300 Amol/L) failed to induce vasoconstriction (Fig. 3d) or changes in Ca 2+ i (n = 12). Since the SMA is not perfused or innervated in our model, the release of endothelial autacoids and neuronal factors is likely absent. In vivo, these autacoids and neuronal factors are likely to modify the potency of S1P with respect to vasoconstriction. To substantiate this principle, we determined the vasoconstrictor response to S1P in the presence of acetylcholine (1 Amol/L), which is known to stimulate the release of endothelial autacoids (e.g., nitric oxide, prostacyclin, EDHF). Consistent with our hypothesis, the presence of acetylcholine significantly shifted the EC 50 of S1P from 3.8 Â 10 À 7 mol/L to 6.0 Â 10 À 5 mol/L (n = 5). Apparent Ca 2+ -sensitivity of the SMA contractile apparatus was assessed by increasing extracellular Ca 2+ (from 0 to 10mmol/L) under depolarizing conditions (125 mmol/L K + ). This procedure leads to a new equilibrium for any given extracellular calcium concentration between forced calcium influx through L-type channels and defensive cellular mechanisms to reduce intracellular calcium (i.e., calcium pumps).
Time-matched control experiments (n = 6) indicated that the apparent Ca 2+ -sensitivity of the SMA was stable over the 30-min experimental period (data not shown). Stimulation of the SMA with 30 nmol/L S1P, a concentration that did not significantly pre-constrict the SMA, elicited a significant increase in Ca 2+ -sensitivity (n = 6; Fig. 4a ). The Rho kinase inhibitor Y27632 (1 Amol/L) not only prevented this leftward shift in sensitivity, it resulted in a substantial reduction in Ca 2+ -sensitivity compared to the control (n = 5; Fig. 4a ). All Ca 2+ -sensitivity data represent paired observations; the measured maximal vessel diameter (dia max ), measured at 0 mmol/L Ca 2+ ex under depolarizing conditions (125 mmol/L K + ), was not altered by any of the treatments (control: 84 T 8, n = 6; S1P: 83 T 8, n = 6; S1P + Y27632: 85 T 9, n = 5). Based on the Fura-2 ratio determinations, intracellular Ca 2+ levels were not different in control, S1P-and S1P + Y27632-treated SMAs at any of the applied extracellular Ca 2+ concentrations (Fig. 4a) . Y27632-treatment alone also profoundly reduced Ca 2+ -sensitivity in the SMA (Fig. 4b) .
RhoA translocation in response to S1P
Immunohistochemical experiments demonstrated that RhoA was localized to the cytosol and possessed a relatively homogenous distribution in control vessels (representative image in Fig. 5a ). Following stimulation with S1P, RhoA was clearly localized to the plasma membrane, indicative of translocation (n = 5; representative image in Fig. 5b ). This observation strongly supports the conclusion that the RhoA signalling in the SMA is activated in response to S1P.
Discussion
When we developed our SMA model beyond the existing ones (i.e., cannulation and pressurization), it was immediately clear that defining the transmural pressure for the SMA would be a challenging task. From an anatomical perspective, the feeding vessel of the SMA (labyrinthine artery) should have a near-systemic pressure (measured by Hata et al. to be 85 mm Hg [14] ). The SMA itself feeds, via small branches, into capillary beds. Therefore, the pressure needs to drop over the length of the SMA. Indeed, the structure of the SMA (i.e., its extensive length), confers an ability to exert considerable resistance to blood flow over its length. Therefore, we expect the in vivo pressure at the distal end of the artery (which we employ for experiments) to be relatively close to the capillary perfusion pressure.
To validate this reasoning, we conducted preliminary experiments over a range of transmural pressures (20 -60 mm Hg). We found that when the SMA was pressurized beyond 30 mm Hg (the pressure we use for all experiments in the present study), most vessel segments were unresponsive to constricting stimuli (data not shown). It is tempting to speculate that because in vivo the SMA is contained within the modiolar bone, the relatively weak, single layer smooth muscle wall may be protected against damage at higher transmural pressures. Such physical support is not present in our model, perhaps rendering the vessel more susceptible to damage from higher pressurization.
In principle, any mediator that increases SMA tone, whether bloodborne or synthesized within the vascular wall, can potentially induce a ''stroke-like'' inner ear pathology. We proposed that sphingosine-1-phosphate (S1P) is such a mediator with pathological potential: (i) S1P is a bloodborne substance [10] ; (ii) it is synthesized by endothelial [15] and smooth muscle cells [11] ; (iii) it induces RhoA/Rho kinasedependent vasoconstriction [6] by modulating the apparent Ca 2+ -sensitivity of the contractile apparatus [6, 11] ; and (iv) its synthesis is induced by a number of pathologically relevant mediators (TNF-a, growth factors, oxidized lipoproteins, etc [5, 16, 17] ).
The enzymes which generate and degrade S1P (Sk1 and SPP1) are expressed at the mRNA level in the SMA, as are three specific receptors, S1P 1 -3 . As a caveat, verification of their protein expression remains to be completed, due to the following limitations: (i) commercially available antibodies are mostly directed against human epitopes and are rather unreliable in non-human tissue; and (ii) the availability of specific inhibitors against these enzymes and receptors is still lacking.
While S1P induces vasoconstriction of mesenteric, cerebral [7] and skeletal muscle [6] microcirculatory beds, contractile responses to S1P are largely absent in conduit arteries (i.e., aorta, carotid and femoral arteries [7, 18] ). S1P-induced vasoconstriction correlates with the expression of S1P 2 and S1P 3 receptors [18] , which both can activate the pro-constrictive RhoA/Rho kinase pathway [19] .
In cannulated and pressurized SMAs, S1P induced dosedependent, Rho kinase-dependent vasoconstriction. The vasoconstriction was associated with a transient increase in smooth muscle Ca 2+ ; this short-lived response, however, did not account for the persistent part of the constriction. According to the measured Ca 2+ /diameter relationship (Fig.  4a) , persistent elevation of intracellular Ca 2+ (in depolarized arteries) resulted in rather limited vasoconstriction. However, the presence of S1P, even at a near-threshold concentration, substantially enhanced the apparent Ca 2+ -sensitivity. Our suggestion that S1P targets RhoA/Rho kinase signalling to prominently regulate of SMA tone is supported by two key observations: (i) the translocation of smooth muscle cell RhoA from the cytosol to the plasma membrane following S1P stimulation, as demonstrated in the present study, indicates RhoA activation [20] ; and (ii) inhibition of Rho kinase blocks S1P-mediated vasoconstriction and results in a drastically reduced apparent Ca 2+ -sensitivity. Modulation of Ca 2+ -sensitivity, therefore, might represent the dominant mechanism for regulating SMA tone. The prominent role of RhoA/Rho kinase signalling is further supported by our experiments indicating that basal Rho kinase activity in the SMA is high (Fig. 4b) . This observation provides a mechanistic rationale for the suggested clinical use of RhoA activity-reducing drugs, such as HMG-CoA reductase inhibitors [21] , in the treatment of acute phase SSHL.
Interestingly, the prominent dependence of SMA tone on RhoA/Rho kinase signalling is in remarkable contrast to the tone-regulating mechanisms of most other vascular beds, where Ca 2+ -dependent mechanisms dominate [6] . In systemic resistance arteries, Ca 2+ -dependent mechanisms often mediate sympathetic activation. The lack of noradrenaline responses in the SMA segments studied (likely due to an absence of adrenergic receptors) further supports our hypothesis that a separate regulatory system controls SMA tone.
The EC 50 for S1P-induced vasoconstriction (115 nmol/L) corresponded well with the reported plasma concentration (191 T 79 nmol/L (10)). Since the SMA endothelium provides a relatively impermeable barrier [22] , it is unlikely that plasma S1P concentrations are reached within the SMC microenvironment under normal physiological conditions. Further, the release of endothelial autacoids in vivo, which can shift the dose -response relationship to S1P, could also serve as both a protecting and modulatory mechanism. The release of neuronal factors could serve a similar role as well.
However, an inflammatory state could compromise endothelial barrier function and autacoid production [23, 24] , allowing plasma S1P to reach the VSMCs. Blood-borne inflammatory mediators (e.g., TNF-a, oxLDL) could further exacerbate this situation by stimulating the intramural S1P synthesis [5, 15, 25] , resulting in strong SMA vasoconstriction that compromises cochlear blood flow. Since S1P dramatically enhances the apparent Ca 2+ -sensitivity, even relatively low intramural S1P concentrations (i.e.,¨10 fold lower than plasma concentrations) are likely sufficient to cause a detrimental increase in vascular resistance. In this context, it is interesting to hypothesize that alterations in SMA resistance do not primarily result from prominent diameter changes over the relatively short length of systemic resistance arteries. Rather, according to Poiseuille's law, the relatively long, convoluted length of the SMA (Fig. 1 ) allows moderate diameter changes to substantially impact vascular resistance and hence, cochlear blood flow.
To possess clinical relevance, the intramural S1P concentration must increase in response to pathological stimuli. Such an event can reasonably occur by (i) passage of S1P from the blood into the vessel wall under circumstances of increased endothelial permeability [24] or (ii) increased synthesis of S1P from cells of the vessel wall (under the condition of bacterial [2] or viral inflammation [26, 27] , autoimmune responses [28] or increased transmural stretch [11] ). However, measurement of intramural S1P levels and the (inflammatory) conditions that alter them were beyond the scope of the present study.
In summary, we report that S1P potently constricts the SMA by a RhoA/Rho kinase-dependent mechanism of Ca 2+ sensitization. While the causal origin of several inner ear pathologies is unknown, many share a common link of vascular inflammation. The high sensitivity to S1P suggests that SMA vasoconstriction is likely to occur under inflammatory conditions that increase intramural S1P concentrations (from plasma or via stimulation of intramural S1P synthesis), resulting in inner ear stroke. From a clinical perspective, the present study identifies the mediators of S1P bioavailability and signalling as new potential therapeutic targets for the treatment of vascular-based inner ear pathologies.
